healthŌme Acquires Kailos Genetics
May 31, 2023
healthŌme Inc. has acquired Kailos Genetics, a CLIA-certified and CAP-accredited genetic testing laboratory, making Kailos a wholly-owned subsidiary to expand healthŌme's genomics testing capabilities. The deal integrates Kailos' laboratory facilities, proprietary sequencing workflow and reagent supply capabilities into healthŌme's precision health management platform, expanding distribution into life and critical illness insurance channels and broader healthcare and life-science markets.
- Buyers
- healthŌme Inc.
- Targets
- Kailos Genetics, LLC
- Industry
- Biotechnology
- Location
- Alabama, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Outcomes4Me Acquires Geno.Me and Realyze Intelligence
May 21, 2026
Healthcare Services
Outcomes4Me, a direct-to-patient AI cancer care platform, completed its acquisitions of Geno.Me and Realyze Intelligence to expand its AI-driven cancer treatment and clinical trial access capabilities. Geno.Me provides patient data access and secure sharing via major EHR integrations, while Realyze Intelligence uses AI to abstract medical records into structured oncology data models for faster clinical trial matching.
-
NeoGenomics Acquires Pathline
April 7, 2025
Healthcare Services
NeoGenomics, Inc. (NASDAQ: NEO) has completed its acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified pathology laboratory headquartered in Ramsey, New Jersey. The deal strengthens NeoGenomics' commercial presence in the Northeast United States and expands its molecular and hematology-oncology testing capabilities and access to its oncology test menu.
-
Principle Health Systems Acquires Telos PGX
December 9, 2024
Healthcare Services
Principle Health Systems has acquired Telos PGX, a CLIA/COLA pharmacogenetic testing provider focused on the long-term care market. The acquisition adds pharmacogenetic testing capabilities to Principle's mobile diagnostic services and will keep Telos founder D.J. Hart in a leadership role to scale operations and expand PGx adoption in skilled nursing facilities.
-
Ginkgo Bioworks Acquires Proof Diagnostics
February 28, 2024
Biotechnology
Ginkgo Bioworks has acquired Proof Diagnostics to integrate Proof's OMEGA nuclease libraries and portable diagnostic technologies into Ginkgo’s gene therapy and genetic medicines platform. The deal expands Ginkgo’s gene editing toolkit and diagnostic capabilities to better serve customers developing programmable medicines and rapid detection systems.
-
Kindbody Acquires Phosphorus Labs
June 7, 2022
Biotechnology
Kindbody has acquired Phosphorus Labs, a preventative genomics and clinical genetic-testing company, including Phosphorus’s 8,000 sq. ft. reference laboratory in Secaucus, New Jersey. The acquisition brings genetic testing and carrier screening capabilities in-house as Kindbody creates its KindLabs division to integrate diagnostics into its end-to-end fertility and family-building care.
-
OncoCyte Corporation Acquires Insight Genetics
January 10, 2020
Healthcare Services
OncoCyte Corporation agreed to acquire all outstanding capital stock of Insight Genetics, a privately held molecular diagnostics company, for approximately $12 million in cash and stock plus potential contingent payments. The acquisition adds Insight Genetics' IM Score immuno-oncology diagnostic test and a pharma-trial–capable CLIA/CAP lab to OncoCyte's portfolio to expand its capabilities in oncology diagnostics and pharma services.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.